Erlotinib in the treatment of advanced pancreatic cancer

Biologics: Targets and Therapy

Volumn 2, Issue 1, 2008, Pages 83-95

  Kelley, Robin K ^a   Ko, Andrew H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

EGFR; Erlotinib; Pancreas; Pancreatic; Tarceva

Indexed keywords

EID: 77953510570     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Abou-Alfa GK, Letourneau R, Harker G, et al. 2006. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol, 24:4441-7.
2. Arteaga C. 2001. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol, 19(18s):32s-40s.
3. Bell DW, Lynch TJ, Haserlat SM, et al. 2005. Epidermal growth factor receptor mutations and gene amplifi cation in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefi tinib trials.J Clin Oncol, 23:8081-92.
4. Berlin JD, Catalano P, Thomas JP, et al. 2002. Phase III study of gemcitabine in combination with fl uorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol, 20:3270-5.
5. Blaszkowsky LS, Kulke KH, Ryan KP, et al. 2005. A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancer. J Clin Oncol, 23(16S):abstract 4099.
6. Bloomston M, Bhardwaj A, Ellison E et al. 2006. Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Dig Surg, 23:74-9.
7. Bruns CJ, Solorzano CC, Harbison MT, et al. 2000. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res, 60:2926-34.
8. Burris HA, Moore MJ, Andersen J, et al. 1997. Improvements in survival and clinical benefi t with gemcitabine as fi rst-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol,15:2403-13.
9. Cappuzzo F, Hirsch FR, Rossi E, et al. 2005. Epidermal growth factor receptor gene and protein and gefi tinib sensitivity in non small-cell lung cancer. J Nat Cancer Inst, 97:643-55.
10. Cappuzzo F, Ligorio C, Janne PA, et al. 2007. Prospective study of gefi tinib in epidermal growth factor receptor fl uorescence in situ hybridization- positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol, 25:2248-55.
11. Chung KY, Shia J, Kemeny N, et al. 2005. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor by immunohistochemistry. J Clin Oncol, 23:1803-10.
12. Cohenuram M and Saif M. 2007. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present, and the future.J Pancreas, 8:4-15.
13. Cunningham D, Chau I, Stocken D, et al. 2005. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. ECCO 13 European Cancer Conference: abstract PS11.
14. Dent P, Reardon DB, Park JS, et al. 1999. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiationinduced cell death. Mol Biol Cell, 10:2493-506.
15. Dragovich T, Huberman M, von Hoff DD, et al. 2007. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemother Pharmacol, 60:295-303.
16. Duffy A, Kortmansky J, Schwartz GK, et al. 2008. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol, 19:86-91.
17. Durkin AJ, Osborne DA, Yeatman TJ, et al. 2006. EGF receptor antagonism improves survival in a murine model of pancreatic carcinoma. J Surg Res, 135:195-201.
18. Eberhard DA, Johnson BE, Amler LC, et al. 2005. Predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol, 23:5900-9.
19. Epelbaum R, Schnaider J, Gluzman A, et al. 2007. Erlotinib as a single-agent therapy in patients with advanced pancreatic cancer. ASCO Gastrointestinal Cancers Symposium: abstract 202.
20. Gatzemeier U, Pluzanska A, Szczesna A, et al. 2007. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trial.J Clin Oncol, 25:1545-52.
21. Gomez-Martin C, Camara JC, Cortes H, et al. 2007. A phase I study of erlotinib, bevacizumab, and gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol, 25(18s): abstract 4611.
22. Grandis JR and Sok JC. 2004. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther, 102:37-46.
23. Gridelli C, Maione P, Amoroso D, et al. 2007. Clinical signifi cance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: Results of an Experts Panel Meeting. Crit Rev Onc. In press.
24. Grunwald V and Hidalgo M. 2003. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Nat Cancer Inst, 95:851-67.
25. Heinemann V, Hinke A, Böck S, et al. Gemcitabine-based combinations (gem+x) vs gemcitabine (gem) alone in the treatment of advanced pancreatic cancer: a meta-analysis of sixteen randomized trials. J Clin Oncol, 25(18s): abstract 4515.
26. Heinemann V, Labianca R, Hinke A, Louvet C. 2007. Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol, 18(10):1652-9.
27. Herrmann R, Bodoky G, Ruhstaller T, et al. 2007. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol, 25:2212-7.
28. Hidalgo M, Siu L, Nemunaitis J, et al. 2001. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol, 19:3267-79.
29. Hirsch FR, Varella-Garcia M, Cappuzzo F, et al. 2007. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefi tinib.Annals of Oncology, 18:752-60.
30. Hirsch FR, Varella-Garcia M, McCoy J, et al. 2005. Increased epidermal growth factor recptor gene copy number detected by fl uorescence in situ hybridization associates with increased sensitivity to gefi tinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol, 23:6838-45.
31. Huang SM, Bock JM, Harari PM. 1999. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of head and neck. Cancer Res, 59:1935-40.
32. Jemal A, Siegel R, Ward E, et al. 2007. Cancer statistics 2007. CA Cancer J Clin, 57:43-66.
33. Kindler HL, Bylow KA, Hochster HS, et al. 2006. A randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis. J Clin Oncol, 24(18s): abstract 4040.
34. Ko AH, Dito E, Schillinger B, et al. 2007. A phase II trial of bevacizumab plus erlotinib for patients with metastatic gemcitabine-refractory pancreatic cancer. ASCO Gastrointestinal Cancers Symposium: abstract 187.
35. Kolb A, Keelf J, Arnold N, et al. 2006. Expression and differential signaling of heregulins in pancreatic cancer cells. Int J Cancer, 120:514-23.
36. Krishnan S, Brown PD, Ballman KV, et al. 2006. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. Int J Radiat Oncol Biol Phys, 65:1192-9.
37. Kwak EL, Jankowski J, Thayer SP, et al. 2006. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.Clin Cancer Res, 12:4283-7.
38. Lammering G, Valerie K, Lin PS, et al. 2001. Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor. Clin Cancer Res, 7:682-90.
39. Lee J, Jang KT, Ki CS, et al. 2007. Impact of epidermal growth factor receptor(EFGR) kinase mutations, EGFR gene amplifi cations, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer, 109:1561-9.
40. Lenz H-J, Van Cutsem E, Khambata-Ford S, et al. 2006. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fl uoropyrimidines. J Clin Oncol, 24:4914-21.
41. Li J, Kleef J, Giese N, et al. 2004. Gefi tinib (Iressa, ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. Int J Oncol, 25:203-10.
42. Louvet C, Labianca R, Hammel P, et al. 2005. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol, 23:3509-16.
43. Lynch TJ, Bell DW, Sordella R, et al. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall- cell lung cancer to gefi tinib. N Engl J Med, 350:2129-39.
44. Marshall J. 2006. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer, 107:1207-18.
45. Mendelsohn J and Baselga J. 2003. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol, 21: 2787-2799.
46. Moore MJ, Goldstein D, Hamm J, et al. 2005. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). J Clin Oncol, 23(16s): abstract 1.
47. Moore MJ, da Cunha Santos G, Kamel-Reid S, et al. 2007a. The relationship of K-ras mutations and EGFR gene copy number to outcome in patients treated with erlotinib on National Cancer Institute of Canada Clinical Trials Group trial study PA.3. J Clin Oncol, 25(18S): abstract 4521.
48. Moore MJ, Goldstein D, Hamm J, et al. 2007b. Erlotinib plus gemictabine compared to gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 25:1960-6.
49. Moyer JD, Barbacci EG, Iwata KK, et al. 1997. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res, 57:4838-48.
50. Murphy LO, Cluck MW, Lovas S, et al. 2001. Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions. Brit J Cancer, 84:926-935.
51. Ng SS, Tsao MS, Nicklee T, et al. 2002. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.Mol Cancer Ther, 1:777-83.
52. Oettle H, Post S, Neuhaus P, Gellert K, et al. 2007. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer. JAMA, 297:267-77.
53. Paez JG, Janne PA, Lee JC, et al. 2004. EGFR mutations in lung cancer: correlation with clinical response to gefi tinib therapy. Science,304:1497-500.
54. Pao W, Miller VA. 2005. Epidermal growth factor receptor mutations, smallmolecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23:2556-68.
55. Perez-Soler R, Saltz L. 2005. Cutaneous adverse effects with HER1/EGFRtargeted agents: is there a silver lining? J Clin Oncol, 23:5235-46.
56. Philip PA, Benedetti J, Fenoglio-Preiser C, et al. 2007. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol, 25 (18s): abstract LBA4509.
57. Pollack VA, Savage DM, Baker DA, et al. 1999. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther, 291:739-48.
58. Porterfi eld BW, Dragovich T, Patnaik A, et al. Erlotinib + gemcitabine in patients with unresectable pancreatic carcinoma: results from a phase IB trial. J Clin Oncol, 22(14S): abstract 4110.
59. Rocha Lima CM, Green MR, Rotche R, et al. 2004. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol,22:3776-83.
60. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, et al. 1997. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene, 15:1191-7.
61. Segaert S and Van Cutsem E. 2005. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol, 16:1425-33.
62. Shepherd FA, Tsao MS. 2006. Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol, 24:1219-20.
63. Soulieres D, Senzer NN, Vokes EE, et al. 2004. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrpsine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol, 22:77-85.
64. Takano T, Ohe Y, Sakamoto H, et al. 2005. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefi tinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol, 23:6829-37.
65. Tejpar S, Peeters M, Humblet Y, et al. 2007. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), pharmacodynamic (PD), and effi cacy data.J Clin Oncol, 25(18s): abstract 4037.
66. Tobita K, Kijima H, Dowaki S, et al. 2003. Epidermal growth factor receptor expression in human pancreatic cancer: signifi cance for liver metastases. Int J Mol Med, 11:305-9.
67. Tzeng CW, Frolov A, Frolova N, et al. 2007. Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery, 141:464-9.
68. Tzeng CW, Frolov A, Frolova N, et al. 2007. Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism infl uences postoperative patient survival and in vitro erlotinib response. Ann Surg Onc, 14:2150-8.
69. Ueda S, Ogata S, Tsuda H, et al. 2004. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness; poor prognosis in patients with pancreatic ductal adenocarcinoma.Pancreas, 29:e1-8.
70. Wacker B, Nagrani T, Weinberg J, et al. 2007. Correlation between development of rash and effi cacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res, 13:3913-21.
71. Yarden Y, Sliwkowski M. 2001. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol, 2:127-37.
72. Yip D, Karapetis C, Strickland A, et al. 2006. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev, 3:CD002093.
73. Yamanaka Y, Friess H, Kobrin MS, et al. 1993. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res, 13:565-9.